脓毒症急性肾损伤的血液净化治疗

Blood purification therapies for septic acute kidney injury

脓毒症急性肾损伤是危重症患者常见并发症,发病率和死亡率均较高。传统血液净化疗法如高容量血液滤过、多黏菌素B血液吸附、配对血浆滤过吸附、高截留量血液滤过等在脓毒症治疗上虽已取得部分临床疗效,但血液净化治疗脓毒症的机制、时机、剂量、频率等问题尚不明了。本课题组研发的生物反应器和粒细胞吸附等新型血液净化技术对脓毒症的治疗作用在动物实验中已得到初步证实。尽管处于初步研究阶段,但新型血液净化技术为脓毒症的血液净化治疗提供了新思路。

Septic acute kidney injury is the common complication in the critically ill patients with high morbidity and mortality. Blood purification techniques, such as high-volume hemofiltration （HVHF）, coupled plasma hemofiltrationadsorption （CPFA）, high cut-off hemofiltration, represent a class of therapies for sepsis that have gain promising pre-clinical and early clinical results, but have not yet been translated into routine clinical practice. There are several explanations for the lack of translation of experimental findings from blood purification studies into clinical practice. For example, the mechanism, timing, dosage, frequency of blood purification in the clinical setting remained unknown. We designed two new kinds of blood purification devices, EBR and SCD, for the treatment of sepsis. In animal models, both of the interventions could alter the natural history of sepsis. Though in the primary research stage, novel blood purification therapies have put forward new insights for the therapy of septic acute kidney injury.